section name header

Indications

REMS


Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Idacio, Hyrimoz, Yuflyma, and YusimryAbrilada, Amjevita, Cyltezo, Hadlima, Humira, Hyrimoz, Yuflyma, and Yusimry onlyAbrilada, Amjevita, Cyltezo, Hadlima, Hulio, and Humira only

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

Route/Dosage

Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis

Crohn's Disease

Ulcerative Colitis

Juvenile Idiopathic Arthritis

Plaque Psoriasis

Uveitis

Hidradenitis Suppurativa

US Brand Names

Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Yuflyma, Yusimry

Action

  • Neutralizes and prevents the action of tumor necrosis factor (TNF), resulting in anti-inflammatory and antiproliferative activity.
Therapeutic effects:
  • Decreased pain and swelling with decreased rate of joint destruction in patients with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.
  • Reduced signs and symptoms and maintenance of clinical remission of Crohn's disease.
  • Induction and maintenance of clinical remission of ulcerative colitis.
  • Reduced severity of plaques.
  • Reduced number of abscesses and inflammatory nodules.
  • Decreased progression of uveitis.

Classifications

Therapeutic Classification: antirheumatics

Pharmacologic Classification: dmards, monoclonal antibodies

Pharmacokinetics

Absorption: 64% absorbed after SUBQ administration.

Distribution: Synovial fluid concentrations are 31–96% of serum.

Metabolism/Excretion: Unknown.

Half-Life: 14 days (range 10–20 days).

Canadian Brand Names

Amgevita, Simlandi

Time/Action Profile

(improvement)

ROUTEONSETPEAKDURATION
SUBQ8–26 wk131 hr*2 wk

*Plasma concentration.

Following discontinuation.

Patient/Family Teaching

Pronunciation

a-da-li-MU-mab

Code

NDC Code